New Targets Identified for Chronic Autoimmune Disease Treatment

Two types of cytokines responsible for the chronic nature of autoimmune disorders has been identified in a recent study.

Autoimmune disorders affect up to 50 million individuals in the United States. They develop when the body’s immune system begins to attack healthy tissue.

Prior studies have linked Th17 cells–– a subset of T cells––to various autoimmune disorders, including inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis. When Th17 cells are activated, a subset will become memory cells and stay in the body for long periods of time. Eventually, these cells will reactivate and cause flare-ups of the autoimmune condition.

Until now, it was unknown how these Th17 cells maintained memory.

In a study published in the Journal of Autoimmunity, investigators used a mouse model for dry eye disease to determine which molecular factors were critical for the maintenance of Th17 memory.

“We wanted to know the precise factors that maintain memory in Th17 cells so that we can better understand what is causing chronic autoimmune disorders,” said senior author Reza Dana, MD, MSc, MPH.

The results of the study showed that Interleukin-7 and -16 (IL-7 and IL-15) played a critical role in the survival and homeostatic proliferation of memory Th17 cells. When the investigators neutralized IL-7 and IL-15, they observed a significant reduction in memory Th17 cells.

“By selectively targeting the production and expression of IL-7 and IL-15, we may be able to prevent the development of chronic autoimmune disorders,” Dr Dana said.

The study findings suggest that targeting IL-7 and IL-15 to remove memory Th17 cells could be an effective treatment approach for autoimmune disease. However, the authors noted that more studies are needed to identify different ways to block these factors.

“In the case of dry eye disease, many of the treatments are showing limited efficacy in patients that do not have a highly inflamed eye,” Dr Dana said. “Targeting the chronic, immune nature of autoimmune diseases may be a better strategy for controlling these conditions.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Patients undergoing chemotherapy can use Emend with other antiemetic medicines to prevent chemotherapy-related nausea and vomiting.
Patients with cancer were less likely to receive standard drugs and interventions for heart attack than patients without cancer.
The monoclonal antibody dupilumab may be effective treating active moderate-to-severe eosinophilic esophagitis.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2017
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.